On December 20th, 2024, the Court of Appeals for the Federal Circuit issued an important decision in Teva Branded Pharmaceutical Products R&D v. Amneal Pharmaceuticals that impacts Orange Book (OB...
The US Patent and Trademark Office (USPTO) has released a final rule implementing increases to various patent fees, effective January 19, 2025. This will impact 433 patent fees, including the introduc...
In a highly anticipated decision in Allergan v. MSN Labs., the Federal Circuit held yesterday that claims in a first-filed, first-issued, later-expiring patent cannot be invalidated for double patenti...
The USPTO on May 10, 2024, issued a notice of proposed rulemaking (NPRM) raising the requirements for accepting a Terminal Disclaimer (TD) to obviate obviousness-type double patenting (ODP). Specifica...
On August 28, 2023, the Federal Circuit issued a decision in In re Cellect, LLC, affirming the Patent Trial and Appeal Board’s (PTAB) cancellation of claims for obviousness-type double patenting (ODP)...
On May 18, 2023, the Supreme Court issued a decision in Amgen Inc. et al. v. Sanofi et al., Number 21-757, holding that a patent claiming an entire class of processes, machines, manufactures, or compo...